ConductScience.org, home

Comparison · NCT00065182-deaths

IV Topotecan + IV Docetaxel vs IV Docetaxel: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. IV Topotecan + IV Docetaxel vs IV Docetaxel: deaths from any cause. Trial comparisons, record NCT00065182-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00065182-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.850.7940.893wilson
Risk in group 20.8460.7890.89wilson
Risk difference, group 1 minus group 20.00385-0.06740.0754newcombe hybrid score
Risk ratio, group 1 over group 210.9241.09log
Odds ratio, group 1 over group 21.030.5951.78log
Number needed to harm, for one more death from any cause on IV Topotecan + IV Docetaxel than on IV Docetaxel260from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1IV Topotecan + IV Docetaxel
Eligible participants received IV topotecan 3.5 mg/m\^2/day and IV docetaxel 30 mg/m\^2/day on Days 1, 8 and 15 (± 2 days) of every 28 day treatment cycle. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study.
170200EG000
Group 2IV Docetaxel
Eligible participants received single-agent IV docetaxel administered either 75 mg/m\^2/day Day 1 (±2 days) of each 21 day treatment cycle or 35 mg/m\^2/day on Days 1, 8 and 15 (± 2 days) of each 28 day treatment cycle, based on the investigator's choice. Participants received at least 4 cycles of treatment unless disease progression was noted or the participant withdrew from the study.
165195EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Up to 16 months

Source ClinicalTrials.gov

Trial

Title
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
NCT number
NCT00065182
Phases
PHASE2
Conditions
Lung Cancer, Non-Small Cell, Non-Small-Cell Lung Cancer
Interventions
Topotecan/Docetaxel combination, Docetaxel
Lead sponsor
GlaxoSmithKline
Results first posted
2019-06-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00065182-deaths